UNSPSC 51292025: Medifoxamine fumarate

This classification denotes a serotonin agonist and dopamine agonist C16H19NO2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OAG6T7TVU2, chemically known as acetaldehyde, (dimethylamino)-, diphenyl acetal, fumarate (1:1), but more generally known as medifoxamine fumarate, which bears US NIH Compound Identifier 6450232. Most nations, for tariff and trade purposes, schedule medifoxamine fumarate under HS 29225000 and SITC 51467. As of Q4 2014, MEDIFOXAMINE FUMARATE remains US FDA's Preferred Term for this commodity.

SMILES: CN(C)CC(OC1CCCCC1)OC2CCCCC2.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51292025 Medifoxamine fumarate is a Commodity code for a specific pharmaceutical product, but the recent state and local opportunities tagged under it reflect a broader pattern: state agencies and county health systems are procuring naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing vehicles. The code's abstract name does not align with the actual scope of work being solicited — buyers are sourcing multiple pharmaceutical classes and harm-reduction products rather than medifoxamine specifically. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances serving state and local government facilities.

Recent activity shows Seminole County, Florida issuing an IFB (Solicitation IFB60459723LAS) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program serving state agencies and self-insured health plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) with a March 26, 2026 response deadline to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring all products to be available by May 15, 2026 and awarding on price competitiveness (75 percent weight), with a two-year initial term and optional extensions. Purchasing patterns concentrate in Florida, Texas, and the upper Midwest, with cooperative purchasing vehicles playing a significant role in statewide and multi-state procurement.